Cargando…

Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production

The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or...

Descripción completa

Detalles Bibliográficos
Autores principales: Shanmugaraj, Balamurugan, I. Bulaon, Christine Joy, Phoolcharoen, Waranyoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411908/
https://www.ncbi.nlm.nih.gov/pubmed/32635427
http://dx.doi.org/10.3390/plants9070842
_version_ 1783568487689486336
author Shanmugaraj, Balamurugan
I. Bulaon, Christine Joy
Phoolcharoen, Waranyoo
author_facet Shanmugaraj, Balamurugan
I. Bulaon, Christine Joy
Phoolcharoen, Waranyoo
author_sort Shanmugaraj, Balamurugan
collection PubMed
description The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed.
format Online
Article
Text
id pubmed-7411908
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74119082020-08-25 Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production Shanmugaraj, Balamurugan I. Bulaon, Christine Joy Phoolcharoen, Waranyoo Plants (Basel) Review The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed. MDPI 2020-07-04 /pmc/articles/PMC7411908/ /pubmed/32635427 http://dx.doi.org/10.3390/plants9070842 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shanmugaraj, Balamurugan
I. Bulaon, Christine Joy
Phoolcharoen, Waranyoo
Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
title Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
title_full Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
title_fullStr Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
title_full_unstemmed Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
title_short Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
title_sort plant molecular farming: a viable platform for recombinant biopharmaceutical production
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411908/
https://www.ncbi.nlm.nih.gov/pubmed/32635427
http://dx.doi.org/10.3390/plants9070842
work_keys_str_mv AT shanmugarajbalamurugan plantmolecularfarmingaviableplatformforrecombinantbiopharmaceuticalproduction
AT ibulaonchristinejoy plantmolecularfarmingaviableplatformforrecombinantbiopharmaceuticalproduction
AT phoolcharoenwaranyoo plantmolecularfarmingaviableplatformforrecombinantbiopharmaceuticalproduction